Cancer-associated bone disease

Osteoporosis International

Volumn 24, Issue 12, 2013, Pages 2929-2953

  Rizzoli, R ^a   Body, J J ^b   Brandi, M L ^c   Cannata Andia, J ^d   Chappard, D ^e   El Maghraoui, A ^f   Gluer C C ^g   Kendler, D ^h   Napoli, N ⁱ   Papaioannou, A ^j   Pierroz, D D ^k   Rahme, M ^l   Van Poznak, C H ^m   De Villiers, T J ⁿ   El Hajj Fuleihan, G ^l  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF OVIEDO   (Spain)

^e UNIV Angers   (France)

^f MILITARY HOSPITAL MOHAMMED V   (Morocco)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^j MCMASTER UNIVERSITY   (Canada)

^k International Osteoporosis Foundation Switzerland   (Switzerland)

^l AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^m UNIVERSITY OF MICHIGAN   (United States)

ⁿ UNIVERSITY OF STELLENBOSCH   (South Africa)

more..

Author keywords

Bone; Cancer; IOF; Skeletal related events

Indexed keywords

ANASTROZOLE; CHLORAMBUCIL; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENOSUMAB; MITOMYCIN; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; TAMOXIFEN; TOREMIFENE; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; AZOOSPERMIA; BONE DISEASE; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER PREVENTION; CLINICAL DECISION MAKING; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FOLLOW UP; FRACTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOGONADISM; IDIOPATHIC OSTEOPOROSIS; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; LONG TERM EXPOSURE; MULTIPLE MYELOMA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; SPINAL CORD COMPRESSION; SPINE FRACTURE;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; HUMANS; HYPOGONADISM; NEOPLASMS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT;

EID: 84890430333     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2530-3     Document Type: Article

References (198)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. WHO (2011) Global status report on noncommunicable diseases 2010. Description of the global burden of NCDs, their risk factors and determinants. WHO, Geneva
3. Weigelt B, Peterse JL, van 't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591-602
4. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s
5. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66
6. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593
7. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
8. Cazzaniga M, Pronzato P, Leto di Priolo SL, De Matteis A, Di Costanzo F, Passalacqua R, Rosso R, Torri V (2004) Patterns of relapse and modalities of treatment of breast cancer: the 'IRIS' Project, a multicenter observational study. Oncology 66:260-268
9. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655-1664
10. Reuss-Borst M, Hartmann U, Scheede C, Weiss J (2012) Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic. Osteoporos Int 23:1437-1444
11. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS (2005) Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558
12. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181
13. Eastell R (2007) Aromatase inhibitors and bone. J Steroid Biochem Mol Biol 106:157-161
14. McCloskey E (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044-1051
15. Rizzoli R, Body JJ, De Censi A, Reginster JY, Piscitelli P, Brandi ML, European Society for Clinical Economical Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 23:2567-2576
16. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051-1057
17. Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500-504
18. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164
19. Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2006) Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 175:1679-1683, discussion 1683
20. Roodman GD (2009) Pathogenesis of myeloma bone disease. Leukemia 23:435-441
21. Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19:18-54
22. Chappard D, Bouvard B, Basle MF, Legrand E, Audran M (2011) Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review. Morphologie 95:65-75
23. Clézardin P, Teti A (2007) Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 24:599-608
24. Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-2898
25. Pugsley MK, Tabrizchi R (2000) The vascular system. An overview of structure and function. J Pharmacol Toxicol Methods 44:333-340
26. Chappard D, Libouban H, Legrand E, Ifrah N, Masson C, Basle MF, Audran M (2010) Computed microtomography of bone specimens for rapid analysis of bone changes associated with malignancy. Anat Rec (Hoboken) 293:1125-1133
27. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51:3059-3061
28. Jones DH, Nakashima T, Sanchez OH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nat Geosci 440:692-696
29. Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tanko LB, Byrjalsen I (2006) Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev 15:1392-1395
30. Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, Serio M, Maggi M (2001) Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49:267-277
31. Takuwa Y, Masaki T, Yamashita K (1990) The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 170:998-1005
32. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET (2004) Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 21:399-408
33. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702-2706
34. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58:1008-1015
35. Bataille R, Chappard D, Basle M (1995) Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. Br J Haematol 90:721-724
36. Bataille R, Chappard D, Klein B (1992) Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 6:285-295
37. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD Jr (2007) The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109:4470-4477
38. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494
39. Barretina J, Junca J, Llano A, Gutierrez A, Flores A, Blanco J, Clotet B, Este JA (2003) CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 82:500-505
40. Josselin N, Libouban H, Dib M, Ifrah N, Legrand E, Basle MF, Audran M, Chappard D (2009) Quantification of dendritic cells and osteoclasts in the bone marrow of patients with monoclonal gammopathy. Pathol Oncol Res 15:65-72
41. Marcelli C, Chappard D, Rossi JF, Jaubert J, Alexandre C, Dessauw P, Baldet P, Bataille R (1988) Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma. Cancer 62:1163-1170
42. Coleman RE, Lipton A, Roodman GD et al (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36:615-620
43. Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R (2009) Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3:75-88
44. VanderWalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61:139-156
45. Michaud LB (2010) Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 67:S20-30, quiz S31-23
46. Wadhwa VK, Parr NJ (2009) Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy? Urology 73:1347-1351
47. Hadji P (2010) Guidelines for osteoprotection in breast cancer patients on an aromatase inhibitor. Breast Care (Basel) 5:290-296
48. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311
49. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223
50. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820-828
51. Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73-82
52. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729
53. Meistrich ML (2009) Male gonadal toxicity. Pediatr Blood Cancer 53:261-266
54. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923-2932
55. Weilbaecher KN (2000) Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 6:165-174
56. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ (1994) Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588
57. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
58. Hu MI, Gagel RF, Jimenez C (2007) Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep 5:170-178
59. Bouvard B, Hoppe E, Soulie P et al (2012) High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol 23:1151-1156
60. Ghazi M, Roux C (2009) Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. Best Pract Res Clin Rheumatol 23:805-811
61. Reid DM (2009) Prevention of osteoporosis after breast cancer. Maturitas 64:4-8
62. Rozenberg S, Carly B, Liebens F, Antoine C (2009) Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment. Maturitas 64:1-3
63. Yamamoto DS, Viale PH (2009) Update on identifying and managing osteoporosis in women with breast cancer. Clin J Oncol Nurs 13:E18-29
64. McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R (2007) Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 43:2523-2531
65. Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619-629
66. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA, Multiple Outcomes of Raloxifene Evaluation T (2002) Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220
67. Gibson K, O'Bryant CL (2008) Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. J Oncol Pharm Pract 14:139-145
68. Arimidex T, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53
69. Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462
70. Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492
71. Perez EA, Josse RG, Pritchard KI et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629-3635
72. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559-570
73. Napoli N, Rastelli A, Ma C et al (2013) Genetic polymorphism at Val(80) (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer. Bone 55:309-314
74. Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL (2007) Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 14:3551-3559
75. Alibhai SM, Breunis H, Timilshina N et al (2010) Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 28:5038-5045
76. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465-5476
77. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615-1624
78. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S (2004) Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171:2272-2276, quiz 2435
79. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22:2546-2553
80. Allain TJ (2006) Prostate cancer, osteoporosis and fracture risk. Gerontology 52:107-110
81. McLeod N, Huynh CC, Rashid P (2006) Osteoporosis from androgen deprivation therapy in prostate cancer treatment. Aust Fam Physician 35:243-245
82. Moyad MA (2003) Osteoporosis and prostate cancer. Urol Oncol 21:374
83. Smith MR (2003) Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev 29:211-218
84. Smith MR, Egerdie B, Hernandez Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755
85. Ryan CJ, Molina A, Griffin T (2013) Abiraterone in metastatic prostate cancer. N Engl J Med 368:1458-1459
86. Townsend MF, Sanders WH, Northway RO, Graham SD Jr (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545-550
87. Adler RA (2011) Management of osteoporosis in men on androgen deprivation therapy. Maturitas 68:143-147
88. Aksnes LH, Bruland OS (2007) Some musculo-skeletal sequelae in cancer survivors. Acta Oncol 46:490-496
89. Chaganti RK, Parimi N, Lang T, Orwoll E, Stefanick ML, Nevitt M, Lane NE (2010) Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group. Osteoporos Int 21:1307-1316
90. Daniell HW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444
91. Daniell HW, Clark JC, Pereira SE, Niazi ZA, Ferguson DW, Dunn SR, Figueroa ML, Stratte PT (2001) Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer 91:1889-1895
92. Grigsby PW, Perez CA (1986) The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J Urol 135:726-727
93. Igdem S, Alco G, Ercan T, Barlan M, Ganiyusufoglu K, Unalan B, Turkan S, Okkan S (2010) Insufficiency fractures after pelvic radiotherapy in patients with prostate cancer. Int J Radiat Oncol Biol Phys 77:818-823
94. Overgaard M (1988) Spontaneous radiation-induced rib fractures in breast cancer patients treated with postmastectomy irradiation. A clinical radiobiological analysis of the influence of fraction size and dose-response relationships on late bone damage. Acta Oncol 27:117-122
95. El Maghraoui A (2004) Corticosteroid-induced osteoporosis. Presse Med 33:1213-1217
96. Sambrook PN (2005) How to prevent steroid induced osteoporosis. Ann Rheum Dis 64:176-178
97. Sambrook PN, Diamond T, Ferris L, Fiatarone-Singh M, Flicker L, MacLennan A, Nowson C, O'Neill S, Greville H (2001) Corticosteroid induced osteoporosis. Guidelines for treatment. Aust Fam Physician 30:793-796
98. Lustberg MB, Reinbolt RE, Shapiro CL (2012) Bone health in adult cancer survivorship. J Clin Oncol 30:3665-3674
99. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific A, Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23-57
100. Bruder JM, Ma JZ, Basler JW, Welch MD (2006) Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67:152-155
101. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(Suppl 1):S3-18
102. Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057
103. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Reginster JY, Rozenberg S, Kaufman JM (2007) Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 18:1439-1450
104. Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407-1416
105. van den Bergh JP, van Geel TA, Lems WF, Geusens PP (2010) Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 8:131-137
106. Watts NB (2011) The Fracture Risk Assessment Tool (FRAX(R)): applications in clinical practice. J Womens Health (Larchmt) 20:525-531
107. Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395-2411
108. Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407-413
109. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR (2010) Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 183:2200-2205
110. Cameron ID, Gillespie LD, Robertson MC, Murray GR, Hill KD, Cumming RG, Kerse N (2012) Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database Syst Rev 12, CD005465
111. Karlsson MK, Magnusson H, von Schewelov T, Rosengren BE (2013) Prevention of falls in the elderly - a review. Osteoporos Int 24:747-762
112. Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391-420
113. Kanis JA, Johansson H, Oden A et al (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029-1037
114. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
115. McCloskey EV, Vasireddy S, Threlkeld J, Eastaugh J, Parry A, Bonnet N, Beneton M, Kanis JA, Charlesworth D (2008) Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res 23:1561-1568
116. Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C (2004) Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol 172:529-532
117. Costelloe CM, Rohren EM, Madewell JE et al (2009) Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10:606-614
118. Bristow RG (2008) Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface. Cancer Metastasis Rev 27:337-338
119. Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF (1999) Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 23:123-129
120. Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N (2008) Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 33:97-101
121. Yang HL, Liu T, Wang XM, Xu Y, Deng SM (2011) Diagnosis of bone metastases: a meta-analysis comparing (1)(8)FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604-2617
122. Cook GJ (2010) PET and PET/CT imaging of skeletal metastases. Cancer Imaging 10:1-8
123. Keaveny TM, Kopperdahl DL, Melton LJ 3rd, Hoffmann PF, Amin S, Riggs BL, Khosla S (2010) Age-dependence of femoral strength in white women and men. J Bone Miner Res 25:994-1001
124. Keyak JH, Kaneko TS, Rossi SA, Pejcic MR, Tehranzadeh J, Skinner HB (2005) Predicting the strength of femoral shafts with and without metastatic lesions. Clin Orthop Relat Res 439:161-170
125. Tanck E, van Aken JB, van der Linden YM, Schreuder HW, Binkowski M, Huizenga H, Verdonschot N (2009) Pathological fracture prediction in patients with metastatic lesions can be improved with quantitative computed tomography based computer models. Bone 45:777-783
126. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10:872-876
127. Morgan GJ, Davies FE, Gregory WM et al (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989-1999
128. Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2, CD003474
129. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321
130. Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405
131. Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
132. Lipton A, Siena S, Rader M, Bilynsky B, Viniegra M, Richardson G, Beuzeboc P, Clemens MR, Ke C, Jun S (2010) Comparison of denosumab versus zoledronioc acid (za) for treatment of bone diseases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Annal Oncol 21(viii):379
133. MacKenzie M, Quinton-Gladstone C, Haynes AE, Hotte S (2010) Zoledronic acid for the treatment of bone metastases secondary to renal cell carcinoma. Toronto (ON): Cancer Care Ontario program in Evidence-based Care CED-CCO Special Advice Report No 18
134. Möbus V, Diel IJ, Harbeck N, et al. (2011) GAIN Study: a phase III trial to compare ETC. vs. EC-TX and Ibandronate vs. observation in patients with node-positive primary breast cancer- 1st interim efficacy analysis. 34th annual CTRC-AACR San Antonio Breast Cancer Symposium
135. S0307 Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer. http://clinicaltrialsgov/ct2/show/NCT00127205?term=s0307&rank=2. Accessed June 2013
136. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
137. Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-5139
138. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
139. Smith MR (2011) Denosumab to prevent bone metastasis-free survival in men with castrate-resistant prostate cancer: results of a global Phase 3, randomised, double-blind trial. AUA meeting Washington DC: Oral presentation
140. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132
141. Brown JE, Barrios CH, Diel IJ et al (2010) Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. Bone Suppl 1:S18-S19
142. Doyle C, Kushi LH, Byers T et al (2006) Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 56:323-353
143. Schmitz KH, Courneya KS, Matthews C et al (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42:1409-1426
144. WCRF/AICR (2007) Food, nutrition and the prevention of cancer: a global perspective expert report. WCRF/AICR, London
145. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266-281
146. Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial. J Bone Miner Res 20:1327-1333
147. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514
148. Geisler J, Lonning PE, Krag LE et al (2006) Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 42:2968-2975
149. Neuhouser ML, Sorensen B, Hollis BW et al (2008) Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 88:133-139
150. Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M, Armamento-Villareal R (2010) High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. Breast J 16:609-616
151. Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi
152. Rizzoli R, Boonen S, Brandi ML, Bruyere O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G, Reginster JY (2013) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 29(4):305-313
153. Bolland MJ, Grey A, Reid IR (2013) Calcium supplements and cardiovascular risk in the Women's Health Initiative. Osteoporos Int 24(8): 2371-2372
154. Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227
155. Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281-300
156. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955-962
157. Fuleihan Gel H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90:3209-3214
158. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26:4739-4745
159. Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E (2010) Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 95:559-566
160. Kim JE, Ahn JH, Jung KH et al (2011) Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 125:99-106
161. Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708
162. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347
163. Shapiro CL, Halabi S, Hars V et al (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47:683-689
164. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C (2001) Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373-2378
165. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967-975
166. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342
167. Greenspan SL, Resnick NM, Nelson JB (2006) Once weekly oral alendronate prevents bone loss in men on androgen deprivation therapy for prostate cancer. J Urol 175(suppl 4):975, abstract
168. Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P (2010) Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 106:1473-1476
169. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038-1042
170. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118:81-87
171. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882
172. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy. http://wwwclinicaltrialsgov/ct2/ show/NCT00556374?term=denosumab+and+cancer&rank=10. Accessed June 2013
173. Saad F, Smith MR, Egerdie B, Tammela TL, Feldman RA, Heracek J, Szwedowski M, Ke C, Leder B, Goessl C (2009) Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer. J Clin Oncol 27:15s, abstract 5056
174. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS (2010) Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 184:1316-1321
175. Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841-3846
176. Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472
177. Terpos E, Morgan G, Dimopoulos MA et al (2013) International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 31:2347-2357
178. Van Poznak CH, Von Roenn JH, Temin S (2011) American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract 7:117-121
179. Lentle B, Cheung AM, Hanley DA, et al. (2011) Osteoporosis Canada 2010 Guidelines for the Assessment of Fracture Risk. Can Assoc Radiol J 62(4):243-250
180. Leslie WD, Schousboe JT (2011) A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr Osteoporos Rep 9:129-140
181. Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864-1873
182. Watts NB, Bilezikian JP, Camacho PM et al (2010) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(Suppl 3):1-37
183. Coleman R, Costa L, Saad F et al (2011) Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 80:411-432
184. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
185. Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30-44
186. Watts NB, Lewiecki EM, Bonnick SL et al (2009) Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 24:1643-1646
187. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546-2555
188. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572-583
189. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420-432
190. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M, International Society of Geriatric Oncology (2007) International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43:852-858
191. Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL, Smith IE (2012) UK guidance document: treatment of metastatic breast cancer. Clin Oncol (R Coll Radiol) 24:169-176
192. Bird JM, Owen RG, D'Sa S et al (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32-75
193. Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303-1317
194. Lacy MQ, Dispenzieri A, Gertz MA et al (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047-1053
195. National Comprehensive Cancer Network (2012) NCCN Guidelines version 1.2012 Multiple Myeloma.
196. Harrouseau JL, Greil R, Kloke O, Force EGT (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol 16(Suppl 1):i45-47
197. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD (2011) Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 194:301-306
198. Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C (2006) The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 4:257-262